http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-930016095-A
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2300-00 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-29 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-48 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-70 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-341 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-20 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-34 |
| filingDate | 1993-01-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 1993-08-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | KR-930016095-A |
| titleOfInvention | Pharmaceutical composition for the treatment of gastrointestinal diseases |
| abstract | It shall present invention having as, acid secretion suppressing function according to a bismuth one kind of ranitidine, 1 H 2 antagonist species and Suk production method of LAL The pharmaceutical composition and a formulation for gastrointestinal diseases containing sulfate tidin and , A bismas agent having a gastric ulcer reinhibition function selected from bismas subsalicylate, bismas subcitrate, and sucralate having a neutralizing gastric acid and promoting regeneration of mucus cells. It is a pharmaceutical composition which consists of 1-2 weight part, 2-4 weight part, 6-12 weight part, especially 1-1.5: 2: 6 weight part of ranitidine, the bismas product, and sucralate.n n n More specifically, it is composed of 50-300 mg of ranitidine, 100-400 mg of bismas subcitrate and 300-3000 mg of sucralate, and the weight ratio of 1-1.5: 2: 6 is used for tablets, capsules, solutions, and core tablets. It is formulated with a capsule containing double tablets or small particles, and is a useful invention that is very effective in preventing and treating gastrointestinal diseases and regenerating gastric mucosa even when formulated at less than half the amount of each single drug. |
| priorityDate | 1992-01-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 30.